{
  "ticker": "RIGL",
  "company_name": "Rigel Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06566742",
      "title": "A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance",
      "start_date": "2024-12-10",
      "completion_date": "2029-08-31",
      "enrollment": 0,
      "sponsor": "M.D. Anderson Cancer Center"
    },
    {
      "nct_id": "NCT06639724",
      "title": "Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "start_date": "2024-12-05",
      "completion_date": "2028-12",
      "enrollment": 0,
      "sponsor": "University of California, San Diego"
    },
    {
      "nct_id": "NCT06782542",
      "title": "Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Acute Myeloid Leukemia, IDH1 Mutation",
      "start_date": "2026-02-01",
      "completion_date": "2029-02-01",
      "enrollment": 0,
      "sponsor": "Justin Watts, MD"
    },
    {
      "nct_id": "NCT04543279",
      "title": "Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Myelofibrosis, Thrombocytopenia",
      "start_date": "2021-05-03",
      "completion_date": "2022-07-30",
      "enrollment": 0,
      "sponsor": "Washington University School of Medicine"
    },
    {
      "nct_id": "NCT04629703",
      "title": "Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral",
      "start_date": "2021-03-25",
      "completion_date": "2022-09-05",
      "enrollment": 0,
      "sponsor": "Rigel Pharmaceuticals"
    },
    {
      "nct_id": "NCT07032727",
      "title": "Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Targeted Therapy, IDH1-Mutated Malignancies, Mutations",
      "start_date": "2025-09-12",
      "completion_date": "2029-06-01",
      "enrollment": 0,
      "sponsor": "M.D. Anderson Cancer Center"
    },
    {
      "nct_id": "NCT00115089",
      "title": "7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Rhinitis, Allergic, Seasonal",
      "start_date": "2005-07",
      "completion_date": "2005-09",
      "enrollment": 0,
      "sponsor": "Rigel Pharmaceuticals"
    },
    {
      "nct_id": "NCT00665925",
      "title": "Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Rheumatoid Arthritis",
      "start_date": "2008-05",
      "completion_date": "2009-06",
      "enrollment": 0,
      "sponsor": "Rigel Pharmaceuticals"
    },
    {
      "nct_id": "NCT05040698",
      "title": "Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hidradenitis Suppurativa",
      "start_date": "2021-10-01",
      "completion_date": "2023-01-27",
      "enrollment": 0,
      "sponsor": "Holdsworth House Medical Practice"
    },
    {
      "nct_id": "NCT04138927",
      "title": "A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE3",
      "condition": "Warm Antibody Autoimmune Hemolytic Anemia",
      "start_date": "2019-10-30",
      "completion_date": "2024-04",
      "enrollment": 0,
      "sponsor": "Rigel Pharmaceuticals"
    }
  ],
  "summary": {
    "total_trials": 40,
    "by_phase": {
      "PHASE2": 23,
      "PHASE1": 5,
      "PHASE3": 6,
      "PHASE1, PHASE2": 4,
      "": 2
    },
    "by_status": {
      "RECRUITING": 10,
      "TERMINATED": 2,
      "COMPLETED": 22,
      "ENROLLING_BY_INVITATION": 1,
      "NOT_YET_RECRUITING": 2,
      "NO_LONGER_AVAILABLE": 1,
      "WITHDRAWN": 2
    },
    "active_trials": 11,
    "completed_trials": 22,
    "conditions": [
      "Acute Myeloid Leukemia",
      "Acute Myeloid Leukemia, IDH1 Mutation",
      "Acute Respiratory Distress Syndrome, ARDS",
      "Asthma",
      "Chronic Graft Versus Host Disease",
      "Chronic Graft-versus-host Disease",
      "Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms, IDH1-mutated Higher-Risk Myelodysplastic Syndromes",
      "Coronavirus, Covid19, Pneumonia",
      "Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral",
      "Hidradenitis Suppurativa",
      "High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma",
      "IGA Nephropathy",
      "ITP, Immune Thrombocytopenia",
      "Immune Thrombocytopenic Purpura",
      "Keratoconjunctivitis Sicca",
      "Low Risk Myelodysplastic Syndromes",
      "Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic",
      "Lymphoma",
      "Mutant IDH1 Inhibitor Olutasidenib",
      "Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance",
      "Myelofibrosis, Thrombocytopenia",
      "Ovarian Cancer",
      "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "Purpura, Thrombocytopenic, Idiopathic",
      "Rheumatoid Arthritis",
      "Rhinitis, Allergic, Seasonal",
      "Systemic Lupus Erythematosus",
      "T Cell Lymphoma",
      "Targeted Therapy, IDH1-Mutated Malignancies, Mutations",
      "Warm Antibody Autoimmune Hemolytic Anemia"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:31.692162",
    "search_query": "Rigel Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Rigel+Pharmaceuticals,+Inc."
  }
}